Tempus AI Soars 1.92% on $700M Surge in Trading Volume Ranks 145th in Market Activity Amid AI Healthcare Expansion

On September 5, 2025, Tempus AI (TEM) rose 1.92% to $79.00, with a trading volume of $0.70 billion, a 47.84% increase from the previous day, ranking it 145th in market activity. The stock has gained 135.84% year-to-date, outperforming the S&P 500’s 10.20% return.

Recent developments highlight Tempus’s strategic expansion in AI-driven healthcare. The company finalized an $81 million acquisition of digital pathology firm Paige to bolster its AI model development. This follows a partnership with Northwestern Medicine to integrate Tempus’s generative AI tools into clinical workflows, enhancing diagnostic efficiency. Analysts at TD Cowen raised the price target for TEM, citing growth in genomic data volumes and improved operational metrics.

Investor sentiment has been supported by a new collaboration with Novartis, which could expand Tempus’s role in personalized medicine. Despite recent insider selling, institutional investors like Hsbc and Jasper Ridge Partners have increased stakes, signaling confidence in long-term potential. A price target hike to $85 by BTIG underscores optimism about the company’s AI healthcare leadership.

The backtesting engine currently supports single-ticker analysis and cannot construct or rebalance multi-stock portfolios automatically. Users are advised to specify a single security or index for testing, or propose an alternative strategy compatible with individual assets.